Rexahn Drugs Deal a Death Blow to Solid Tumor Cancer

May 19, 2016 | 9:15 am

Efficacy in Gemzar-resistant cancer is proven

In rapid-fire fashion, striking clinical trial results for Rexahn Pharmaceuticals’ (RNN) drugs are hitting news. From preclinicals to people, in under four years, two anti-cancer therapies – Archexin and RX-3117 that target tumors at the cellular level to either shrink or kill, posted recent impressive results. Medical recognition is growing with each presentation of data, and the green light to continue larger clinical trials is lit.

– Investor network –

Click here for more information